SNYNF News and Press, Sanofi From 04/25/24

2024-04-25 01:38:35 ET More on Sanofi: Sanofi: My Top Pick In Big Pharma Sanofi reportedly lining up banks for consumer products spinoff Sanofi succeeds in late-stage trial for blood disorder candidate Read the full article on Seeking Alpha For furthe...

Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS (1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€...

2024-04-23 09:44:51 ET More on Sanofi Sanofi: My Top Pick In Big Pharma Sanofi (SNY) Barclays 26th Annual Global Healthcare Conference (Transcript) Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript) Sanofi reportedly settles 4K Zantac case...

Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITP Regu...

2024-04-17 01:50:40 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis 96% of participants receiving high-dose int...

2024-04-16 14:16:55 ET Summary Just as the "Magnificent 7" stocks lead returns and headlines in US markets, an 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. Here I run a head-to-head comparison using the Magnificent 7 as a proxy for the Invesco QQQ ET...

2024-04-12 12:02:53 ET More on AbbVie, Biogen, etc. AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% Novo Nordisk: The Moat Won't Last Forever AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision No link between weight...

2024-04-12 07:05:43 ET More on Eli Lilly, Novo Nordisk, etc. Novo Nordisk: The Moat Won't Last Forever Eli Lilly: Three Threats To Its Huge Rally Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data Roche, Eli Lilly gain ...

2024-04-09 14:15:55 ET More on Nurix, Sanofi, etc. Sanofi: My Top Pick In Big Pharma Sanofi (SNY) Barclays 26th Annual Global Healthcare Conference (Transcript) Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript) Sanofi agrees to settle ~4K...